Sign In
Buy ALPN
$64.97
+0 (+0%)
At Close: Aug 19, 2024
US Stock Futures Edge Higher; All Eyes On Fed Decision
09:12am, Wednesday, 21'st Sep 2022 Benzinga
Pre-open movers
U.S. stock futures traded slightly higher in early pre-market trade on Wednesday after recording losses on Tuesday. The Dow Jones closed lower by more than 300 points, while the Nasdaq
General Mills, Lennar And 3 Stocks To Watch Heading Into Wednesday
08:23am, Wednesday, 21'st Sep 2022 Benzinga
With US stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Wall Street expects General Mills, Inc. (NYSE: GIS) to r
Alpine Immune Sciences, Inc. (ALPN) Moves to Buy: Rationale Behind the Upgrade
04:00pm, Monday, 15'th Aug 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alpine Immune Sciences, Inc. (ALPN) Moves to Buy: Rationale Behind the Upgrade
01:32pm, Monday, 15'th Aug 2022
Alpine Immune Sciences, Inc. (ALPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates
11:55am, Thursday, 04'th Aug 2022 Zacks Investment Research
Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?
01:42pm, Friday, 24'th Jun 2022 Zacks Investment Research
Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Thursday, 12'th May 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
07:34pm, Thursday, 12'th May 2022
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
09:45pm, Monday, 09'th May 2022 Zacks Investment Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Endo International (ENDP) Surpasses Q1 Earnings and Revenue Estimates
11:15pm, Thursday, 05'th May 2022 Zacks Investment Research
Endo (ENDP) delivered earnings and revenue surprises of 50% and 1.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences Announces Participation in May Investor Conferences
08:05am, Tuesday, 03'rd May 2022
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflamma
Alpine: Rest Before Rallying Again
12:08pm, Monday, 25'th Apr 2022
Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leade
Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study
10:00am, Wednesday, 13'th Apr 2022
Alpine Immune Sciences Inc (NASDAQ: ALPN) announced the oral presentation of results from the dose-escalation portion of NEON-1 study of davoceticept monotherapy in advanced malignancies. The data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease
Aeglea BioTherapeutics Inc (NAS
Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock?
01:30pm, Thursday, 24'th Mar 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further
